Roundtable Charter

The Institute of Medicine’s Roundtable on Value & Science-Driven Health Care has been convened to help transform the way evidence on clinical effectiveness is generated and used to improve health and health care. Participants have set a goal that, by the year 2020, ninety percent of clinical decisions will be supported by accurate, timely, and up-to-date clinical information, and will reflect the best available evidence. Roundtable members will work with their colleagues to identify the issues not being adequately addressed, the nature of the barriers and possible solutions, and the priorities for action, and will marshal the resources of the sectors represented on the Roundtable to work for sustained public-private cooperation for change.

Vision: Our vision is for the development of a continuously learning health system in which science, informatics, incentives, and culture are aligned for continuous improvement and innovation—with best practices seamlessly embedded in the care process, patients and families active participants in all elements, and new knowledge captured as an integral by-product of the care experience.

Goal: By the year 2020, ninety percent of clinical decisions will be supported by accurate, timely, and up-to-date clinical information, and will reflect the best available evidence. We feel that this presents a tangible focus for progress toward our vision, that Americans ought to expect at least this level of performance, that it should be feasible with existing resources and emerging tools, and that measures can be developed to track and stimulate progress.

Context: As unprecedented developments in the diagnosis, treatment, and long-term management of disease bring Americans closer than ever to the promise of personalized health care, we are faced with similarly unprecedented challenges to identify and deliver the care most appropriate for individual needs and conditions. Care that is important is often not delivered. Care that is delivered is often not important. In part, this is due to our failure to apply the evidence we have about the medical care that is most effective—a failure related to shortfalls in provider knowledge and accountability, inadequate care coordination and support, lack of insurance, poorly aligned payment incentives, and misplaced patient expectations. Increasingly, it is also a result of our limited capacity for timely generation of evidence on the relative effectiveness, efficiency, and safety of available and emerging interventions. Improving the value of the return on our healthcare investment is a vital imperative that will require much greater capacity to evaluate high priority clinical interventions, stronger links between clinical research and practice, and reorientation of the incentives to apply new insights. We must quicken our efforts to position evidence development and application as natural outgrowths of clinical care—to foster health care that learns.

Approach: The IOM Roundtable on Value & Science-Driven Health Care serves as a forum to facilitate the collaborative assessment and action around issues central to achieving the vision and goal stated. The challenges are myriad and include issues that must be addressed to improve evidence development, evidence application, and the capacity to advance progress on both dimensions. To address these challenges, as leaders in their fields, Roundtable members work with their colleagues to identify the issues not being adequately addressed, the nature of the barriers and possible solutions, and the priorities for action, and marshal the resources of the sectors represented on the Roundtable to work for sustained public-private cooperation for change.

Activities include collaborative exploration of new and expedited approaches to assessing the effectiveness of diagnostic and treatment interventions, better use of the patient care experience to generate evidence on effectiveness and efficiency of care, identification of assessment priorities, and communication strategies to enhance provider and patient understanding and support for interventions proven to work best and deliver value in health care.
**Core concepts and principles:** For the purpose of the Roundtable activities, we define science-driven health care broadly to mean that, to the greatest extent possible, the decisions that shape the health and health care of Americans—by patients, providers, payers and policymakers alike—will be grounded on a reliable evidence base, will account appropriately for individual variation in patient needs, and will support the generation of new insights on clinical effectiveness. Evidence is generally considered to be information from clinical experience that has met some established test of validity, and the appropriate standard is determined according to the requirements of the intervention and clinical circumstance. Processes that involve the development and use of evidence should be accessible and transparent to all stakeholders.

A common commitment to certain principles and priorities guides the activities of the Roundtable and its members, including the commitment to: the right health care for each person; putting the best evidence into practice; establishing the effectiveness, efficiency and safety of medical care delivered; building constant measurement into our healthcare investments; the establishment of healthcare data as a public good; shared responsibility distributed equitably across stakeholders, both public and private; collaborative stakeholder involvement in priority setting; transparency in the execution of activities and reporting of results; and subjugation of individual political or stakeholder perspectives in favor of the common good.

Mark McClellan, MD, PhD *(Chair)*
Brookings Institution

Raymond J. Baxter, PhD
Kaiser Permanente

Paul Bleicher, MD, PhD
Optum Labs

David Blumenthal, MD, MPP
The Commonwealth Fund

Bruce G. Bodaken, MPhil
Blue Shield of California

Paul Chew, MD
Sanofi US

Helen Darling, MA
Nat Business Group on Health

Susan D. DeVore
Premier, Inc.

Judith Faulkner, MS
Epic Systems

Patricia A. Gabow, MD
Denver Health

Atul Gawande, MD, MPH
Brigham & Women’s Hospital

Gary L. Gottlieb, MD, MBA
Partners HealthCare System

James A. Guest, JD
Consumers Union

George C. Halvorson
Kaiser Permanente

James Heywood
PatientsLikeMe

Ralph I. Horwitz, MD
GlaxoSmithKline

Paul Hudson
AstraZeneca

Brent C. James, MD, MStat
Intermountain Healthcare

Craig A. Jones, MD
VT Blueprint for Health

Gary Kaplan, MD
Virginia Mason Health System

Darrell G. Kirch
AAMC

Richard C. Larson
Mass Institute for Technology

Peter Long, PhD
Blue Shield of California Foundation

James L. Madara, MD
American Medical Association

Mary D. Naylor, PhD, RN
UPenn

William D. Novelli, MA
Georgetown University

Sam Nussbaum, MD
WellPoint, Inc.

Jonathan B. Perlin, MD, PhD
HCA, Inc.

Richard Platt, MD, MS
Harvard

Michael Rosenblatt, MD
Merck & Company, Inc.

John W. Rowe, MD
Columbia University

Joe Selby, MD, MPH
Executive Director, PCORI

Leonard D. Schaeffer
USC Price

Mark D. Smith, MD, MBA
CA HealthCare Foundation

Glenn D. Steele, MD, PhD
Geisinger Health System

Reed V. Tuckson, MD
Connections, LLC

Debra Whitman, PhD, MA
AARP

Richard J. Umbdenstock
American Hospital Association

**Ex Officio**

Francis Collins, MD, PhD
National Institutes of Health
(Kathy Hudson, PhD, MS)

Thomas Frieden, MD, MPH
Centers for Disease Control & Prevention
(James Galloway, MD; Chesley Richards, MD, MPH)

Margaret A. Hamburg, MD
Food and Drug Administration
(Peter Lurie MD, MPH)

Richard Kronick, PhD
Agency for HC Research & Quality

Robert A. Petzel, MD
Department of Veterans Affairs

Jacob Reider, MD
Office of the Nat Coordinator for HIT

Marilyn Tavenner, MHA, RN
Centers for Medicare & Medicaid Services
(Patrick Conway, MD, MS)

Mary Wakefield, PhD, RN
Health Resources & Services Admin

Jonathan Woodson, MD
Department of Defense

*Members as of Dec 2013*